Suggested remit - To appraise the clinical and cost effectiveness of luspatercept within its marketing authirsation for treating beta-thalassaemia
|
Status
|
Proposed
|
| Process |
STA 2018
|
| ID number |
1554
|
Provisional Schedule
| Committee meeting: 1 |
08 July 2020 |
| Expected publication |
16 September 2020 |
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Consultees
| Companies sponsors |
Celgene (luspatercept) |
| Others |
Department of Health and Social Care |
| |
NHS Bexley CCG |
| |
NHS England |
| |
NHS West London CCG |
| |
Welsh Government |
| Patient carer groups |
Black Health Agency |
| |
Bloodwise |
| |
Equalities National Council |
| |
Genetic Alliance UK |
| |
Muslim Council of Britain |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
UK Thalassaemia Society |
| Professional groups |
British Blood Transfusion Society |
| |
British Society for Bone Marrow Transplantation (BSBMT) |
| |
British Committee for Standards in Haematology |
| |
British Society for Haematology |
| |
NHS Blood & Transplant |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
UK Clinical Pharmacy Association |
| |
UK Forum on Haemoglobin Disorders |
| |
UK Haemophilia Centre Doctors’ Organisation |
| |
UK National Screening Committee |
Commentators
| Assessment group |
Cochrane Haematological Malignancies Group |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |
| |
National Primary Care Research & Development Centre |
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Hospira UK (desferrioxamine) |
| |
Novartis Pharmaceuticals (desferrioxamine, deferasirox) |
| |
Swedish Orphan Biovitrum (deferiprone) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Hospital Information Services – Jehovah’s Witnesses |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
25 October 2019
|
Invitation to participate |
|
24 May 2019 - 24 June 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance